425 related articles for article (PubMed ID: 31013788)
1. An Update on Anti-CD137 Antibodies in Immunotherapies for Cancer.
Chu DT; Bac ND; Nguyen KH; Tien NLB; Thanh VV; Nga VT; Ngoc VTN; Anh Dao DT; Hoan LN; Hung NP; Trung Thu NT; Pham VH; Vu LN; Pham TAV; Thimiri Govinda Raj DB
Int J Mol Sci; 2019 Apr; 20(8):. PubMed ID: 31013788
[TBL] [Abstract][Full Text] [Related]
2. Rationale for anti-CD137 cancer immunotherapy.
Makkouk A; Chester C; Kohrt HE
Eur J Cancer; 2016 Feb; 54():112-119. PubMed ID: 26751393
[TBL] [Abstract][Full Text] [Related]
3. Anti-CD137 and PD-1/PD-L1 Antibodies En Route toward Clinical Synergy.
Pérez-Ruiz E; Etxeberria I; Rodriguez-Ruiz ME; Melero I
Clin Cancer Res; 2017 Sep; 23(18):5326-5328. PubMed ID: 28790118
[TBL] [Abstract][Full Text] [Related]
4. CD137 / CD137 ligand signalling regulates the immune balance: A potential target for novel immunotherapy of autoimmune diseases.
Wong HY; Schwarz H
J Autoimmun; 2020 Aug; 112():102499. PubMed ID: 32505443
[TBL] [Abstract][Full Text] [Related]
5. CD137, an attractive candidate for the immunotherapy of lung cancer.
Ye L; Jia K; Wang L; Li W; Chen B; Liu Y; Wang H; Zhao S; He Y; Zhou C
Cancer Sci; 2020 May; 111(5):1461-1467. PubMed ID: 32073704
[TBL] [Abstract][Full Text] [Related]
6. Phase I Study of Single-Agent Utomilumab (PF-05082566), a 4-1BB/CD137 Agonist, in Patients with Advanced Cancer.
Segal NH; He AR; Doi T; Levy R; Bhatia S; Pishvaian MJ; Cesari R; Chen Y; Davis CB; Huang B; Thall AD; Gopal AK
Clin Cancer Res; 2018 Apr; 24(8):1816-1823. PubMed ID: 29549159
[No Abstract] [Full Text] [Related]
7. Anti-CD137 Suppresses Tumor Growth by Blocking Reverse Signaling by CD137 Ligand.
Kang SW; Lee SC; Park SH; Kim J; Kim HH; Lee HW; Seo SK; Kwon BS; Cho HR; Kwon B
Cancer Res; 2017 Nov; 77(21):5989-6000. PubMed ID: 28923858
[TBL] [Abstract][Full Text] [Related]
8. Characterizing CD137 upregulation on NK cells in patients receiving monoclonal antibody therapy.
Makkouk A; Sundaram V; Chester C; Chang S; Colevas AD; Sunwoo JB; Maecker H; Desai M; Kohrt HE
Ann Oncol; 2017 Feb; 28(2):415-420. PubMed ID: 27831501
[TBL] [Abstract][Full Text] [Related]
9. CD137 Stimulation Enhances Cetuximab-Induced Natural Killer: Dendritic Cell Priming of Antitumor T-Cell Immunity in Patients with Head and Neck Cancer.
Srivastava RM; Trivedi S; Concha-Benavente F; Gibson SP; Reeder C; Ferrone S; Ferris RL
Clin Cancer Res; 2017 Feb; 23(3):707-716. PubMed ID: 27496866
[TBL] [Abstract][Full Text] [Related]
10. CD137 (4-1BB) Signalosome: Complexity Is a Matter of TRAFs.
Zapata JM; Perez-Chacon G; Carr-Baena P; Martinez-Forero I; Azpilikueta A; Otano I; Melero I
Front Immunol; 2018; 9():2618. PubMed ID: 30524423
[TBL] [Abstract][Full Text] [Related]
11. Phase Ib Study of Utomilumab (PF-05082566), a 4-1BB/CD137 Agonist, in Combination with Pembrolizumab (MK-3475) in Patients with Advanced Solid Tumors.
Tolcher AW; Sznol M; Hu-Lieskovan S; Papadopoulos KP; Patnaik A; Rasco DW; Di Gravio D; Huang B; Gambhire D; Chen Y; Thall AD; Pathan N; Schmidt EV; Chow LQM
Clin Cancer Res; 2017 Sep; 23(18):5349-5357. PubMed ID: 28634283
[No Abstract] [Full Text] [Related]
12. Immunotherapy of cancer with 4-1BB.
Vinay DS; Kwon BS
Mol Cancer Ther; 2012 May; 11(5):1062-70. PubMed ID: 22532596
[TBL] [Abstract][Full Text] [Related]
13. 4-1BB (CD137), an inducible costimulatory receptor, as a specific target for cancer therapy.
Vinay DS; Kwon BS
BMB Rep; 2014 Mar; 47(3):122-9. PubMed ID: 24499671
[TBL] [Abstract][Full Text] [Related]
14. BT7480, a novel fully synthetic
Hurov K; Lahdenranta J; Upadhyaya P; Haines E; Cohen H; Repash E; Kanakia D; Ma J; Kristensson J; You F; Campbell C; Witty D; Kelly M; Blakemore S; Jeffrey P; McDonnell K; Brandish P; Keen N
J Immunother Cancer; 2021 Nov; 9(11):. PubMed ID: 34725211
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic vaccination with tumor cells that engage CD137.
Hellstrom KE; Hellstrom I
J Mol Med (Berl); 2003 Feb; 81(2):71-86. PubMed ID: 12601523
[TBL] [Abstract][Full Text] [Related]
16. Are peptide vaccines viable in combination with other cancer immunotherapies?
Ohtake J; Sasada T
Future Oncol; 2017 Aug; 13(18):1577-1580. PubMed ID: 28776424
[No Abstract] [Full Text] [Related]
17. Identification of CD137- and CD137L-Expressing Cells in EL-4 Tumor.
Kang SW; Cho HR; Kwon B
Methods Mol Biol; 2021; 2248():221-229. PubMed ID: 33185879
[TBL] [Abstract][Full Text] [Related]
18. Cancer Immunotherapy: The Dawn of Antibody Cocktails.
Marrocco I; Romaniello D; Yarden Y
Methods Mol Biol; 2019; 1904():11-51. PubMed ID: 30539465
[TBL] [Abstract][Full Text] [Related]
19. Harnessing co-stimulatory TNF receptors for cancer immunotherapy: Current approaches and future opportunities.
Waight JD; Gombos RB; Wilson NS
Hum Antibodies; 2017; 25(3-4):87-109. PubMed ID: 28085016
[TBL] [Abstract][Full Text] [Related]
20. Anti-CD137 antibodies in the treatment of autoimmune disease and cancer.
Mittler RS; Foell J; McCausland M; Strahotin S; Niu L; Bapat A; Hewes LB
Immunol Res; 2004; 29(1-3):197-208. PubMed ID: 15181282
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
